"Adjuvants, Immunologic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.
| Descriptor ID |
D000276
|
| MeSH Number(s) |
D27.505.696.477.067
|
| Concept/Terms |
Adjuvants, Immunologic- Adjuvants, Immunologic
- Immunostimulants
- Adjuvant, Immunologic
- Immunologic Adjuvant
- Immunological Adjuvant
- Adjuvant, Immunological
- Immunoactivators
- Immunoadjuvants
- Immunologic Adjuvants
- Immunopotentiators
- Adjuvants, Immunological
- Immunological Adjuvants
|
Below are MeSH descriptors whose meaning is more general than "Adjuvants, Immunologic".
Below are MeSH descriptors whose meaning is more specific than "Adjuvants, Immunologic".
This graph shows the total number of publications written about "Adjuvants, Immunologic" by people in this website by year, and whether "Adjuvants, Immunologic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 2 | 1 | 3 |
| 1997 | 1 | 0 | 1 |
| 1998 | 0 | 1 | 1 |
| 1999 | 3 | 2 | 5 |
| 2000 | 2 | 2 | 4 |
| 2001 | 2 | 2 | 4 |
| 2002 | 1 | 4 | 5 |
| 2003 | 3 | 2 | 5 |
| 2004 | 2 | 3 | 5 |
| 2005 | 3 | 0 | 3 |
| 2006 | 4 | 1 | 5 |
| 2007 | 1 | 2 | 3 |
| 2008 | 3 | 1 | 4 |
| 2009 | 2 | 1 | 3 |
| 2010 | 2 | 3 | 5 |
| 2011 | 2 | 4 | 6 |
| 2012 | 4 | 3 | 7 |
| 2013 | 9 | 3 | 12 |
| 2014 | 3 | 0 | 3 |
| 2015 | 4 | 2 | 6 |
| 2016 | 0 | 5 | 5 |
| 2017 | 4 | 1 | 5 |
| 2018 | 4 | 1 | 5 |
| 2019 | 1 | 2 | 3 |
| 2020 | 3 | 3 | 6 |
| 2021 | 3 | 2 | 5 |
| 2022 | 0 | 4 | 4 |
| 2023 | 0 | 5 | 5 |
| 2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Adjuvants, Immunologic" by people in Profiles.
-
Cysteine-binding adjuvant enhances survival and promotes immune function in a murine model of acute myeloid leukemia. Blood Adv. 2024 Apr 09; 8(7):1747-1759.
-
Saponin TQL1055 adjuvant-containing vaccine confers protection upon Mycobacterium tuberculosis challenge in mice. Hum Vaccin Immunother. 2024 Dec 31; 20(1):2302070.
-
Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies. Eur J Cancer. 2023 12; 195:113404.
-
Nanoscale coordination polymer synergizes photodynamic therapy and toll-like receptor activation for enhanced antigen presentation and antitumor immunity. Biomaterials. 2023 11; 302:122334.
-
Nanovaccine that activates the NLRP3 inflammasome enhances tumor specific activation of anti-cancer immunity. Biomaterials. 2023 05; 296:122062.
-
Size matters in non-canonical inflammasome activation and cell-mediated immunity. Cell Rep Med. 2023 01 17; 4(1):100904.
-
Methods to Study TLRs in Transplantation. Methods Mol Biol. 2023; 2700:139-149.
-
Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials. J Clin Oncol. 2023 03 01; 41(7):1376-1382.
-
Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT. J Clin Oncol. 2023 03 01; 41(7):1370-1375.
-
Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment. J Clin Oncol. 2022 11 10; 40(32):3741-3749.